Gadopentetate-Dimeglumine-Enhanced Magnetic Resonance Imaging for Lung Nodules Differentiation of Lung Cancer and Tuberculoma

Kusumoto, Masahiko; Kono, Michio; Adachi, Shuji; Yamasaki, Katsuhito; Itouji, Eiichiro; Sakai, Eiro; Endo, Masashiro; Nakamura, Tetsu; Kimura, Kazuhiko

doi:10.1097/00004424-199406001-00087

Cited by 25 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signal intensity at the center of tuberculomas is low or slightly enhanced, but the signal intensity of the fibrotic rim is markedly enhanced. These MR findings correspond well to those of pathological specimens (Sakai et al 1992;Kono et al 1993;Kusumoto et al 1994;Parmar et al 2000;Chung et al 2000;Schaefer et al 2006). Therefore, when tuberculoma is suspected or attempts are images show nodule as, respectively, low, intermediate, and high signal intensity in the left lower lobe.…”

Section: Tuberculomasupporting

confidence: 83%

“…2 and 3). It has therefore been suggested that enhancement patterns or blood supply evaluated with dynamic contrast-enhanced MR imaging may be helpful for diagnosis and management of pulmonary nodules (Kono et al 1993(Kono et al , 2007Kusumoto et al 1994;Hittmair et al 1995;Gückel et al 1996;Fujimoto et al 2003;Ohno et al 2002Ohno et al , 2004aSchaefer et al 2004Schaefer et al , 2006Donmez et al 2007). However, it may be possible to diagnose several histological types of pulmonary nodules, such as bronchocele, tuberculoma, mucinous bronchoalveolar carcinoma (BAC), hamartoma, and aspergilloma, on pre-or post-contrastenhanced T1-weighted images and T2-weighted image according to their specific MR findings.…”

Section: Characterization and Management Of Pulmonary Nodules Or Massmentioning

confidence: 99%

“…In rare cases, areas of diminished attenuation are seen, which represent caseous necrosis. The latter may be identified as tuberculoma, a nodule with a relatively low signal intensity in comparison with that of other pulmonary nodules on T2-weighted SE or turbo SE images (Sakai et al 1992;Kono et al 1993;Kusumoto et al 1994;Parmar et al 2000;Chung et al 2000;Schaefer et al 2006). In addition, several investigators have reported on typical MR findings of tuberculoma on post-contrast-enhanced T1-weighted images known as "thin-rim enhancement" sign (Sakai et al 1992) (Fig.…”

Section: Tuberculomamentioning

confidence: 99%

“…Although in some cases benign or malignant focal lesions can be differentiated from others by using pre-and post-contrast-enhanced conventional T1-or T2-weighted SE or turbo SE imaging, significant overlaps have been observed between benign and malignant lesions in routine clinical practice (Kono et al 1993;Kusumoto et al 1994). To overcome this problem, dynamic contrast-enhanced MR imaging has been proposed as an alternative technique for diagnosis and/or management of pulmonary nodules (Table 1).…”

Section: Dynamic Contrast-enhanced Mr Imaging Of Pulmonary Nodulesmentioning

confidence: 99%

“…These curves represent first transit and/or recirculation and washout of contrast media in irregularly thickened cavity wall as, respectively, low and high signal intensities in the left lower lobe. Post-contrast black-blood T1-weighted turbo SE (e) image shows wellenhanced cavity wall corresponding to lung cancer 5 min or more with repeated breath holding (Kono et al 1993(Kono et al , 2007Kusumoto et al 1994;Hittmair et al 1995;Gückel et al 1996;Ohno et al 2002Ohno et al , 2004aFujimoto et al 2003;Schaefer et al 2004Schaefer et al , 2006Donmez et al 2007). Taking into account the inherent inhomogeneous composition of many intraindividual lung cancers and even within benign lesions such as central necrosis, only a dynamic show intracavitary lesion as, respectively, low and very low signal intensities in the left upper lobe.…”

Section: Dynamic Contrast-enhanced Mr Imaging Of Pulmonary Nodulesmentioning

confidence: 99%

See 4 more Smart Citations

Lung Cancer

Ohno¹,

Koyama²,

Dinkel³

2016

MRI of the Lung

View full text Add to dashboard Cite

Since the publication of the Radiologic Diagnostic Oncology Group Report (RDOG) in 1991, the clinical application of pulmonary magnetic resonance (MR) imaging to patients with lung cancer has been limited. MDCT has been much more widely available for staging of lung cancer in clinical situations. Traditionally, FDG-PET or PET/CT is the only modality that reveals biological glucose metabolism of lung cancer, and ventilation and/or perfusion scintigraphy is the only modality that demonstrates pulmonary function. However, recent advances of MR systems and utilization of contrast media make it possible to overcome the limitation of chest MR imaging. Therefore, in the last years, several investigators have demonstrated the significant comprehensive potential of MR imaging to substitute for MDCT and nuclear medicine examinations in lung cancer staging. Currently, MR imaging in lung cancer patients can be applied for (1) detection of pulmonary nodules, (2) characterization of solitary pulmonary nodules, and (3) assessment of TNM classification in routine clinical practice. We believe that further basic studies, as well as clinical applications of newer MR techniques, will play an important role in the future management of patients with lung cancer including MRI.

show abstract

Section: Tuberculomasupporting

confidence: 83%

Section: Characterization and Management Of Pulmonary Nodules Or Massmentioning

confidence: 99%

Section: Tuberculomamentioning

confidence: 99%

Section: Dynamic Contrast-enhanced Mr Imaging Of Pulmonary Nodulesmentioning

confidence: 99%

Section: Dynamic Contrast-enhanced Mr Imaging Of Pulmonary Nodulesmentioning

confidence: 99%

See 3 more Smart Citations

Lung Cancer

Ohno¹,

Koyama²,

Dinkel³

2016

MRI of the Lung

View full text Add to dashboard Cite

show abstract

Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy

Ohno

Nogami

Higashino

et al. 2005

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose:To determine the prognostic value of dynamic MRI for non-small-cell lung cancer (NSCLC) patients after chemoradiotherapy. Materials and Methods:A total of 114 consecutive patients with NSCLC underwent dynamic MRI after chemoradiotherapy. The patients were divided into two groups (local control (n ϭ 22) and local failure (n ϭ 92)) according to the presence of local recurrence. From the signal intensity-time course curve in each subject, the maximum relative enhancement ratio and slope of enhancement were calculated, and compared between two groups by Student's ttest. To determine the feasible threshold values of both MR indexes for group differentiation, ROC-based positive tests were performed. Finally, the Kaplan-Meier survival curves of each group divided by the adapted threshold value were compared by log-rank test. Results:The maximum relative enhancement ratio and the slope of enhancement in the local control group were significantly lower than those in the local failure group (P Ͻ 0.05). Using 0.08/sec as the threshold value of the slope of enhancement, the sensitivity and specificity for differentiation between the two groups were 90.9% and 91.3%, respectively. When the slope of enhancement was adopted for estimation of prognosis after therapy, the mean survival period of the slope of enhancement Յ 0.08/sec group was significantly longer than that seen in the group with a slope of enhancement Ͼ 0.08/sec (P Ͻ 0.0001). Conclusion:Dynamic MRI has potential prognostic value for NSCLC patients after chemoradiotherapy.

show abstract

Dynamic MRI, dynamic multidetector‐row computed tomography (MDCT), and coregistered 2‐[fluorine‐18]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (FDG‐PET)/CT: Comparative study of capability for management of pulmonary nodules

Ohno

Koyama

Takenaka

et al. 2008

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose:To compare the nodule management capabilities of dynamic MRI, dynamic multidetector-row computed tomography (MDCT) and coregistered positron emission tomography (PET)/CT. Materials and Methods:Dynamic MRI, dynamic MDCT, PET, microbacterial, and pathological examinations were administered to 175 consecutive patients with 202 nodules (Ͻ30 mm in diameter). The final diagnoses resulted in the classification of 202 nodules into two groups: requiring further intervention and treatment (N ϭ 163) and no further evaluation (N ϭ 39) groups. Maximum relative enhancement and slope of enhancement ratio were calculated as dynamic MR indices. Maximum enhancement, net enhancement, slope of enhancement, and absolute loss of enhancement were calculated as dynamic CT indices. maximum value of standard uptake value (SUV max ) was measured on coregistered PET/CT. Receiver operating characteristics (ROC) analyses were performed to determine feasible threshold values for nodule management, and results were tested using McNemar's test. Results:When feasibility threshold values were adopted for nodule management, the specificity (82.1%) and accuracy (93.6%) of the slope of the enhancement ratio were significantly higher than those of dynamic CT indices (P Ͻ 0.05) and SUV max (P Ͻ 0.05). Conclusion:Dynamic MRI can play a more specific and/or accurate role for nodule management as compared with dynamic MDCT and coregistered PET/CT.

show abstract

Gadopentetate-Dimeglumine-Enhanced Magnetic Resonance Imaging for Lung Nodules Differentiation of Lung Cancer and Tuberculoma

Cited by 25 publications

References 0 publications

Lung Cancer

Lung Cancer

Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy

Dynamic MRI, dynamic multidetector‐row computed tomography (MDCT), and coregistered 2‐[fluorine‐18]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (FDG‐PET)/CT: Comparative study of capability for management of pulmonary nodules

Contact Info

Product

Resources

About